|Day Low/High||1.91 / 2.07|
|52 Wk Low/High||1.68 / 5.88|
Lpathomab is well-tolerated at all doses tested in healthy volunteers
Company to Present Additional Data From the Nexus Phase 2 Study of iSONEP™
Company Provides Update on Strategic Priorities
These under-$10 stocks look poised to trade higher from current levels. Here's how to trade them.
These stocks rising on unusual volume are within range of triggering breakout trades.
Study Did Not Meet Primary or Key Secondary Endpoints
Conference Call Scheduled for Today at 4:30 p.m. ET to Provide Investor Update
Conference Call Scheduled for Wednesday, December 3rd to Provide Investor Update
Scott Pancoast Resigns as President & CEO; Board Appoints Michael Lack as Interim CEO
Patent Provides Coverage for Lpath's Anti-S1P Antibody in Europe
Based on encouraging progression-free survival data, Lpath extends the study to a second cohort and considers additional proof-of-concept studies
TheStreet highlights 3 stocks pushing the Health Care sector lower today.
SBIR Grant from the National Institutes of Neurological Diseases and Stroke Provides Funds for IND-enabling Studies of Lpathomab
The Department of Defense's WRAIR will study Lpath's anti-LPA antibody in the blast injury model of TBI
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Publication Further Validates Lpath's Approach to Targeting Bioactive Lipids for Drug Discovery